EN | TR
E-ISSN: 3061-9947
Quality of Life in Chronic Myeloid Leukemia Patients in the Era of Generic Imatinib
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 2
P: 245-249
2020

Quality of Life in Chronic Myeloid Leukemia Patients in the Era of Generic Imatinib

Acta Haematol Oncol Turc 2020;53(2):245-249
DOI: 10.5505/aot.2020.40316
Abide Günnur Balcı Güçlü 1
Nur Oğuz Davutoğlu 2
Beyhan Durak Aras 3
Eren Gündüz 2
1. Eskisehir Osmangazi University School of Medicine Department of Internal Medicine, Eskisehir, Turkey
2. Eskisehir Osmangazi University School of Medicine Department of Hematology, Eskisehir, Turkey
3. Eskisehir Osmangazi University School of Medicine Department of Genetics, Eskisehir, Turkey
4.
No information available.
No information available
Received Date: 2019-11-12T22:27:39
Accepted Date: 2020-09-04T10:15:22
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The first line treatment for chronic myeloid leukaemia (CML) is still imatinib mesylate in many countries. Dasatinib and nilotinib are also effective in first line treatment but often used in resistant or intolerant patients. The treatment requires strict drug compliance and regular blood tests. Lifelong treatment as well as regular controls may negatively affect the quality of life. The aim of this study was to evaluate the quality of life of CML patients taking tyrosine kinase inhibitors (TKI).

METHODS

A total of 120 patients were included in the study and divided into 3 groups according to the TKI they take generic imatinib (n=72), dasatinib (n=23) or nilotinib (n=25). EORTC QLQ-CML24 and EORTC QLQ-C30 (version 3.0) scales were used to evaluate the quality of life.

RESULTS

Insomnia in nilotinib group was lower than the dasatinib group (16.00 ± 23.80 vs 28.70± 35.25, p= 0.027). The satisfaction with care information of imatinib group was lower than dasatinib group (75.46± 17.00 vs 84.78± 20.66, p = 0.007). No difference was found between the 3 groups for other parameters.

DISCUSSION AND CONCLUSION

The comparison of chronic myeloid leukemia patients under generic imatinib, dasatinib and nilotinib suggested that the second generation TKIs are generally well tolerated and have nearly similar effects with imatinib on quality of life.